ArticleThe Journal of biological chemistry2026
Neuroprotective role of NRF2 activation against ER Stress-Mediated apoptosis in obstructive sleep apnea.
Article in The Journal of biological chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obstructive sleep apnea (OSA) induces childhood cognitive impairment via chronic intermittent hypoxia (CIH), a process to which endoplasmic reticulum stress (ERS)-mediated apoptosis critically contributes. Nuclear factor erythroid 2-related factor 2 (NRF2) is widely recognized for its significant neuroprotective effects in various neurological diseases, yet its role in ERS-related apoptosis in prefrontal neurons under CIH remains unclear. This study investigated NRF2's impact both in vitro and in vivo. In CIH-exposed Pheochromocytoma 12 (PC12) cells, mimicking OSA-related neuronal injury, CIH significantly triggered ERS and subsequent apoptosis, evidenced by the upregulated protein levels of ERS markers (p-PERK, ATF4, CHOP) and apoptotic markers (Cleaved-Caspase-3). Additionally, the antioxidant system was activated, as shown by elevated mRNA levels of Nrf2, Hmox1, and Gclc and protein levels of NRF2, HO-1, and GCLC. Treatment with the NRF2 activator sulforaphane (SFN) reduced CIH-induced apoptosis by suppressing ERS signaling and enhancing Hmox1 mRNA and HO‑1 protein expression. Conversely, ML385 (a NRF2 inhibitor) resulted in opposite outcomes. In vivo, after 4 weeks of CIH exposure, mice demonstrated spatial memory and learning deficits in the behavior test. In the prefrontal cortex, histological examination revealed increased neuronal apoptosis, characterized by elevated Cleaved-Caspase-3 protein levels, alongside activation of the NRF2 pathway. Treatment with SFN alleviated cognitive impairment and neuronal apoptosis by inhibiting ERS signaling, while enhancing Hmox1 mRNA and HO‑1 protein expression. Conversely, treatment with a NRF2 inhibitor had the opposite effects. In summary, we demonstrate that NRF2 mitigates CIH-induced neuronal apoptosis by suppressing the PERK-ATF4-CHOP signaling cascade and augmenting HO-1 expression, thereby improving cognitive impairment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.